Diagnostic test for cardiomyopathy
AssigneeGenesis Group Inc.
InventorsTerry-Lynn Young, Kathy Hodgkinson, Sean Connors, Patrick Parfrey, Annika Haywood, Nancy Merner, Vanessa French
Life of this patent
Estimating the term…
Loading patent…
AssigneeGenesis Group Inc.
InventorsTerry-Lynn Young, Kathy Hodgkinson, Sean Connors, Patrick Parfrey, Annika Haywood, Nancy Merner, Vanessa French
Estimating the term…
Methods and compositions relating to diagnosing and treating cardiomyopathy and particularly relating to methods and compositions for diagnosing and treating arrhythmogenic right ventricular dysplasia/cardiomyophathy (ARVD/C) are described. Provided are methods for screening for, diagnosing or detecting a risk of developing arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) comprising detecting the presence of a transmembrane protein 43 (TMEM43) disease associated variant in a sample of a subject, wherein the presence of a TMEM43 disease variant is indicative that the subject has ARVD/C or an increased risk of developing ARVD/C compared to an individual having wild type TMEM43.
A method of screening for, diagnosing and/or detecting an increased risk of developing arrhythmogenic right ventricular dysplasia/ cardiomyopathy (ARVD/C) in a subject, comprising determining the presence of one or more ARVD/C mutations in TMEM43 in a sample obtained from the subject, and identifying the subject as having ARVD/C or an increased risk of developing ARVD/C.
A method of identifying a substance which binds mutant TMEM43 comprising one or more ARVD/C mutations comprising:
A composition comprising a mutant TMEM43 polypeptide comprising one or more ARVD/C mutations, an antibody specific for a mutant TMEM43 comprising one or more ARVD/C mutations or at least one isolated nucleic acid, wherein the at least one isolated nucleic acid hybridizes to:
Dependencies are inferred from the claim text.